GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genmab AS GMAB · USD

Health Care · US listing · 🇺🇸 United States

Compare

55.80

+4.05%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$3.72bn

FY2016FY2025

Net income

$963.8m

FY2016FY2025

Free cash flow

$1.15bn

FY2016FY2025

Shareholders' equity

$5.83bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$3.72bn$21.53bn$16.47bn$14.51bn$8.42bn$10.11bn$5.37bn$3.03bn$2.37bn$1.82bn
Gross profit$3.41bn$20.54bn$16.25bn$14.51bn$8.42bn$10.11bn$5.37bn$3.03bn$2.37bn$1.82bn
Research and development$1.56bn$9.75bn$7.63bn$5.56bn$4.18bn$3.14bn$2.39bn$1.43bn$874.3m$660.9m
Operating income$1.25bn$6.70bn$5.32bn$6.27bn$2.95bn$6.31bn$2.64bn$1.38bn$1.34bn$1.05bn
Net income$963.8m$7.84bn$4.35bn$5.45bn$2.96bn$4.76bn$2.17bn$1.47bn$1.10bn$1.19bn
Diluted earnings per share1.4312.236.628.254.477.203.292.371.771.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$12.84bn$45.81bn$35.29bn$30.12bn$24.63bn$21.14bn$15.14bn$8.46bn$6.60bn$5.24bn
Cash and short-term investments$1.71bn$21.10bn$28.14bn$22.32bn$19.34bn$16.08bn$10.97bn$6.11bn$5.42bn$3.92bn
Total liabilities$7.01bn$9.11bn$3.68bn$2.84bn$2.43bn$2.02bn$1.10bn$446.6m$330.8m$411.5m
Debt$5.29bn$92.0m$90.0m$74.0m$62.0m$42.0m$181.0m——$61.6m
Shareholders' equity$5.83bn$36.70bn$31.61bn$27.28bn$22.20bn$19.12bn$14.05bn$8.01bn$6.27bn$4.83bn
Shares outstanding673m642m658m661m661m661m658m621m622m619m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$1.19bn$7.77bn$7.38bn$3.91bn$2.23bn$6.43bn$1.33bn$1.01bn$1.59bn$327.7m
Capital spending−$37.0m−$187.0m−$376.0m−$317.0m−$252.0m−$307.0m−$111.0m−$477.4m−$88.5m−$33.1m
Free cash flow$1.15bn$7.58bn$7.00bn$3.60bn$1.98bn$6.13bn$1.22bn$537.4m$1.50bn$294.6m
Dividends paid———−$280.0m−$135.0m−$115.0m−$9.0m———

Latest quarters

By quarter end

Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024
Revenue$899.3m$1.05bn$1.02bn$924.8m$105.2m$6.44bn$5.54bn$779.0m
Gross profit$834.1m$974.1m$964.0m$867.8m$99.1m$6.10bn$5.27bn$751.0m
Operating income$172.3m$242.3m$459.0m$359.9m$27.7m$2.16bn$2.10bn$236.0m
Net income$53.2m$30.9m$401.0m$335.9m$28.7m$3.85bn$1.27bn$203.0m
Diluted earnings per share0.080.050.600.500.045.991.970.32
Cash from operations$3.0m$300.0m$536.0m$61.0m$286.0m$326.0m$2.03bn$219.0m
Capital spending−$5.0m−$12.0m−$2.0m−$9.0m−$29.0m−$26.0m−$48.0m−$4.0m
Free cash flow−$2.0m$288.0m$534.0m$52.0m$257.0m$300.0m$1.99bn$215.0m
Total assets$12.38bn$12.84bn$7.02bn$6.46bn$6.03bn$45.81bn$39.66bn$38.62bn
Cash and short-term investments$1.52bn$1.71bn$3.41bn$2.90bn$2.70bn$21.10bn$17.32bn$15.73bn
Debt$5.24bn$5.29bn$16.0m$16.0m$14.9m$1.03bn$987.0m$1.02bn
Shareholders' equity$5.68bn$5.83bn$5.75bn$5.30bn$4.95bn$36.70bn$31.92bn$30.97bn

Financial ratios

Data as of 30 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin91.7%95.4%98.6%100.0%100.0%100.0%
Operating margin33.6%31.1%32.3%43.2%35.1%62.4%
Net margin25.9%36.4%26.4%37.6%35.1%47.1%
Return on equity16.5%21.4%13.8%20.0%13.3%24.9%
Return on assets7.5%17.1%12.3%18.1%12.0%22.5%
Free cash flow yield5.1%34.9%33.1%18.0%10.5%28.7%
Revenue growth-82.7%30.7%13.6%72.3%-16.8%88.4%
Earnings growth-87.7%80.2%-20.2%84.4%-37.9%119.7%
Current ratio2.02x5.25x13.34x15.48x14.50x15.00x
Debt to equity0.91x0.00x0.00x0.00x0.00x0.00x
Equity ratio45.4%80.1%89.6%90.6%90.1%90.4%
Interest coverage20.49x55.86x197.07x298.43x227.15x631.30x
R&D as a share of sales41.9%45.3%46.3%38.3%49.7%31.0%
Buybacks as a share of market value-4.8%2.5%0.4%0.1%-0.1%-0.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-36.4%-18.1%12.6%
Operating income-41.6%-27.7%5.5%
Net income-43.9%-27.3%2.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin94.9%97.3%98.0%98.3%
Operating margin31.5%34.8%38.5%40.6%
Net margin34.9%33.1%35.2%37.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings21.51.74.85.18.85.76.87.09.38.7
Price to sales5.60.61.31.93.12.72.73.44.45.7

Market value over time

31 Oct 2016 to 29 Sept 2026, in USD

$1.03bn$21.95bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return56%-36%-27%11%-3%84%33%-1%2%21%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.